20.500.12556/DiRROS-24480 Maternal fatigue after postpartum anemia treatment with intravenous ferric carboxymaltose vs. intravenous ferric derisomaltose vs. oral ferrous sulphate a randomized controlled trial (1) Background: Postpartum anemia is a common maternal complication and is recognized as a cause of impaired quality of life, reduced cognitive abilities, and fatigue. Efficient iron supplementation for the treatment of postpartum anemia is an essential component of high-quality maternal care. The optimal mode of iron supplementation has not been determined yet, whether oral or intravenous. The objective of this study was to compare postpartum anemia treatment with intravenous ferric carboxymaltose, intravenous ferric derisomaltose, and oral ferrous sulfate. (2) Methods: A single-center, open-label, randomized controlled trial. Women with hemoglobin < 100 g/L within 48 h postpartum were randomly allocated to receive intravenous ferric carboxymaltose, intravenous ferric derisomaltose, or oral ferrous sulfate. Intravenous iron was given in one or two doses, while ferrous sulfate was given as two 80 mg tablets once daily. The primary outcome was maternal fatigue measured by the Multidimensional Fatigue Inventory (MFI) six weeks postpartum. Hemoglobin, ferritin, and transferrin saturation levels were analyzed as secondary outcomes. A Kruskal–Wallis test was used for group comparison (p < 0.05 significant). (3) Results: Three hundred women were included. The MFI score at six weeks postpartum did not differ between groups (median 38 (inter-quartile range (IQR) 29–47) in the ferric carboxymaltose group, median 34 (IQR 26–42) in the ferric derisomaltose group, and median 36 (IQR 25–47) in the ferrous sulfate group; p = 0.26). Participants receiving oral iron had lower levels of hemoglobin (135 (131–139) vs. 134 (129–139) vs. 131 (125–137) g/L; p = 0.008), ferritin (273 (198–377) vs. 187 (155–246) vs. 24 (17–37) µg/L; p < 0.001) and transferrin saturation (34 (28–38) vs. 30 (23–37) vs. 24 (17–37) %; p < 0.001) than those receiving ferric carboxymaltose or ferric derisomaltose. (4) Conclusions: Intravenous ferric carboxymaltose, intravenous ferric derisomaltose, and oral ferrous sulfate had similar impacts on maternal fatigue at six weeks postpartum despite improved laboratory parameters in the intravenous groups. postpartum anemia fatigue intravenous iron treatment oral iron replacement patient-centered outcome true false true Angleški jezik Ni določen Neznano 2025-12-01 13:57:44 2025-12-01 13:57:44 2025-12-02 03:42:04 0000-00-00 00:00:00 2024 0 0 Nasl. z nasl. zaslona; Opis vira z dne 19. 2. 2025; str. 1-10 iss. 7, [article no.] 758 Vol. 13 2024 0000-00-00 Zaloznikova Objavljeno apc 0000-00-00 0000-00-00 0000-00-00 61 2077-0383 10.3390/jcm13030758 226639875 RAZ_Bombac_Tavcar_Lea_2024.pdf RAZ_Bombac_Tavcar_Lea_2024.pdf 1 CFFCFE19BFE5C6CC2D1130E08FD96D34 b5a9a518118ce249a55af3623c3a850ee9029cf33d997cb8bbe242dc6086c6a4 7b4df0e6-ceb5-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36477 https://www.mdpi.com/2077-0383/13/3/758 1 56eb0d9b-ceb5-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36476 Univerzitetni klinični center Ljubljana 0 0 0